Figure 3.

Effect of LCI699 and eplerenone on adrenal hormones, serum electrolytes, cardiac and renal parameters in dTG rats. (A) Plasma aldosterone concentrations (PAC); (B) urinary aldosterone excretion (UAldoE); (C) serum potassium; (D) serum sodium; (E) mean arterial pressure (MAP); (F) LV fractional shortening (FS); (G) LV isovolumic relaxation time (IVRT) as a percentage of R-R interval; (H) LV myocardial cell size; (I) 24-h urine volume (V); (J) 24-h urinary albumin excretion (UAE); (K) blood urea nitrogen (BUN) and (L) creatinine clearance (C_Cr). Values are shown for double-transgenic (dTG) rats (triangle), dTG rats treated with LCI699 (3, 10, 30 or 100 mg/kg/day in drinking water) or eplerenone (Epl, 30 mg/kg/day in chow) from 3 to 7 weeks of age (square) and in control Sprague-Dawley (S-D) rats (circle). Eplerenone vehicle controls are depicted separately from LCI699 vehicle controls. Measurements were taken at 7 weeks of age. Values are mean ± SEM. Number of evaluable animals was n = 6 per dose group, with the exception of S-D rat controls (n = 11). *P < 0.05 vs dTG rats. ^† P < 0.05 vs S-D rats.